Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS7 | Q9UKP4 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 6/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | KLK1 | P06870 | 2/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | FPR3 | P25089 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2326982 | 0.84 | ADAMTS7 (0.39) | ADAMTS7MEN1KMT2AALDH1A1FPR3 | |
| SCHEMBL2823806 | 0.76 | ALDH1A1 (0.39) | KLKB1HSD17B10KLK1GABRA5GABRB2 | |
| SCHEMBL1704174 | 0.76 | MAPT (0.40) | MEN1KMT2AALDH1A1FPR3FPR2 | |
| SCHEMBL2328189 | 0.75 | TSHR (0.36) | ALDH1A1FPR3FPR2 | |
| SCHEMBL2329291 | 0.73 | MAPT (0.50) | KLKB1KLK1MEN1KMT2AALDH1A1 | |
| SCHEMBL9900051 | 0.73 | SCN9A (0.38) | — | |
| SCHEMBL2331781 | 0.72 | SMN1; SMN2 (0.34) | ADAMTS7 | |
| SCHEMBL855209 | 0.71 | KMT2A (0.38) | HSD17B10GABRA5GABRB2MEN1KMT2A | |
| SCHEMBL2333791 | 0.69 | KDM4C (0.38) | KLKB1GABRA5GABRB2KDM4E | |
| SCHEMBL1614004 | 0.69 | ALDH1A1 (0.39) | HSD17B10GABRA5GABRB2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536209-B2 | Aminotriazole derivatives as ALX agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-17 | — | — | US | claimed |
| EP-2225231-B1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-08-17 | — | — | EP | claimed |
| US-20100331378-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION (CH) | 2010-12-30 | — | — | US | claimed |
| US-8536209-B2 | Aminotriazole derivatives as ALX agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-17 | — | — | US | disclosed |
| US-20100331378-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION (CH) | 2010-12-30 | — | — | US | disclosed |
| EP-2225231-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009077990-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331378-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ADORA1, ADORA3, TBXA2R | ADAMTS7 2912/4885KLKB1 4485/4885HSD17B10 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.